Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M.

Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.


CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe.

Natarajan G, Ramalingam S, Ramachandran I, May R, Queimado L, Houchen CW, Anant S.

Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1235-44. doi: 10.1152/ajpgi.00037.2008.


Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.

Ouyang G, Yao L, Ruan K, Song G, Mao Y, Bao S.

Cell Biol Int. 2009 Dec;33(12):1237-44. doi: 10.1016/j.cellbi.2009.08.011.


Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage.

Blakemore LM, Boes C, Cordell R, Manson MM.

Carcinogenesis. 2013 Feb;34(2):351-60. doi: 10.1093/carcin/bgs345.


Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM.

Clin Cancer Res. 2002 Aug;8(8):2735-41.


The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.

Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Mar 16;9:1627-52. doi: 10.2147/DDDT.S75378.


Difference of cell cycle arrests induced by lidamycin in human breast cancer cells.

Liu X, He H, Feng Y, Zhang M, Ren K, Shao R.

Anticancer Drugs. 2006 Feb;17(2):173-9.


Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in response to DNA damage.

Monaco L, Kolthur-Seetharam U, Loury R, Murcia JM, de Murcia G, Sassone-Corsi P.

Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14244-8.


Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells.

Dai E, Zhang J, Zhang D, Yang L, Wang Y, Jiang X, Ye L, Li X, Liu H, Ma J, Jiang H.

Hepatogastroenterology. 2014 Oct;61(135):2052-61.


Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.

Xiao Z, Xue J, Gu WZ, Bui M, Li G, Tao ZF, Lin NH, Sowin TJ, Zhang H.

Biomarkers. 2008 Sep;13(6):579-96. doi: 10.1080/13547500802063240 .


GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity.

Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, Mazzacurati L, Li X, Petrik KL, Rajasekaran B, Wu M, Zhan Q.

Oncogene. 2002 Dec 12;21(57):8696-704.


The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P, Bifulco M.

Pharmacol Res. 2012 Mar;65(3):365-71. doi: 10.1016/j.phrs.2011.11.008.


6,7-Dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells.

Chung KS, Choi HE, Shin JS, Cho YW, Choi JH, Cho WJ, Lee KT.

Carcinogenesis. 2013 Aug;34(8):1852-60. doi: 10.1093/carcin/bgt133.


A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.

Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H.

Oncogene. 2005 Feb 17;24(8):1403-11.


The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.

Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, Kroemer G.

Oncogene. 2004 May 27;23(25):4353-61.


Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.

Kaestner P, Stolz A, Bastians H.

Mol Cancer Ther. 2009 Jul;8(7):2046-56. doi: 10.1158/1535-7163.MCT-09-0323.

Items per page

Supplemental Content

Support Center